Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25499382 | 0.97 | DPP7 (0.46) | DPP7DPP8DPP9OPRK1DPP4 | |
| SCHEMBL25499377 | 0.88 | DPP4 (0.48) | DPP7DPP8DPP9OPRK1DPP4 | |
| SCHEMBL26040756 | 0.88 | DPP7 (0.47) | DPP7DPP8DPP9OPRK1DPP4 | |
| SCHEMBL25499375 | 0.87 | DPP4 (0.47) | DPP7DPP8DPP9OPRK1DPP4 | |
| SCHEMBL26040010 | 0.87 | DPP7 (0.46) | DPP7DPP8DPP9OPRK1DPP4 | |
| SCHEMBL25503280 | 0.86 | GNAI3 (0.46) | DPP7DPP8DPP9OPRK1DPP4 | |
| SCHEMBL25503161 | 0.86 | DPP7 (0.45) | DPP7DPP8DPP9OPRK1DPP4 | |
| SCHEMBL25499351 | 0.83 | OPRK1 (0.37) | DPP7DPP8DPP9OPRK1DPP4 | |
| SCHEMBL25499350 | 0.82 | OPRK1 (0.37) | DPP7DPP8DPP9OPRK1DPP4 | |
| SCHEMBL25499341 | 0.80 | OPRK1 (0.39) | DPP7DPP8OPRK1DPP4FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739076-B2 | Compound or its salt thereof targeting fibroblast activation protein, its preparation methods and its uses thereof | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, R.O.C. (TW) | 2023-08-29 | — | — | US | disclosed |
| US-11739076-B2 | Compound or its salt thereof targeting fibroblast activation protein, its preparation methods and its uses thereof | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, R.O.C. (TW) | 2023-08-29 | — | — | US | disclosed |
| US-20230159495-A1 | COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, R.O.C. (TW) | 2023-05-25 | — | — | US | disclosed |
| US-20230159495-A1 | COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, R.O.C. (TW) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739076-B2 | Compound or its salt thereof targeting fibroblast activation protein, its preparation methods and its uses thereof | FIBP, FGFR2, FGFR1 | DPP7 1004/4885DPP8 1186/4885DPP9 1271/4885 |
| US-20230159495-A1 | COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF | FIBP, FGFR2, FGFR1 | DPP7 1004/4885DPP8 1186/4885DPP9 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.